S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
New CBOE “special perk” helps traders target income every weekend (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
New CBOE “special perk” helps traders target income every weekend (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
New CBOE “special perk” helps traders target income every weekend (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
15 best consumer discretionary stocks for the rest of 2023
New CBOE “special perk” helps traders target income every weekend (Ad)
Energy traders: A rebound is coming
Kroger shares are begging to be bought 
New CBOE “special perk” helps traders target income every weekend (Ad)
Behind the tech boom: Big price leaders selectively laying off
Dallas Mavericks purchase turns LVS stock into a cheaper bet
New CBOE “special perk” helps traders target income every weekend (Ad)
Earnings propel Crowdstrike, cybersecurity sector, to new highs
These biotechs targeting multiple neurodegenerative diseases

Biora Therapeutics Stock Price, News & Analysis (NASDAQ:BIOR)

$1.35
+0.11 (+8.87%)
(As of 12/1/2023 ET)
Compare
Today's Range
$1.24
$1.61
50-Day Range
$1.21
$2.62
52-Week Range
$1.18
$7.68
Volume
12.23 million shs
Average Volume
442,928 shs
Market Capitalization
$32.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Biora Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.18mentions of Biora Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.55) to ($2.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.37 out of 5 stars

Medical Sector

901st out of 954 stocks

Pharmaceutical Preparations Industry

419th out of 439 stocks


BIOR stock logo

About Biora Therapeutics Stock (NASDAQ:BIOR)

Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

BIOR Stock Price History

BIOR Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
BIOR: 3Q:23 Results
Q3 2023 Biora Therapeutics Inc Earnings Call
Recap: Biora Therapeutics Q3 Earnings
Biora Therapeutics earnings: here's what Wall Street expects
Earnings Outlook For Biora Therapeutics
See More Headlines
Receive BIOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biora Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOR
Fax
N/A
Employees
54
Year Founded
N/A

Profitability

Net Income
$-38,160,000.00
Net Margins
-55,269.39%
Pretax Margin
-677,261.06%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
($5.01) per share

Miscellaneous

Free Float
18,209,000
Market Cap
$32.00 million
Optionable
Optionable
Beta
1.22
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Aditya P. Mohanty M.B.A. (Age 56)
    CEO & Director
    Comp: $858.82k
  • Mr. Eric d'Esparbes (Age 55)
    Executive VP & CFO
    Comp: $651.91k
  • Mr. Clarke Neumann J.D. (Age 59)
    Senior VP, General Counsel & Secretary
    Comp: $624.13k
  • Eric Fox
    VP of Finance & Accounting & Treasurer
  • Mr. Troy Seelye (Age 59)
    Chief Information Officer
  • Mr. George Gianakopoulos (Age 62)
    Senior Vice President of Sales
  • Ms. Robyn Hatton
    Head of Human Resources
  • Mr. Kevin Howe Ph.D.
    Senior VP of Strategic Operations
  • Dr. Sharat Singh Ph.D. (Age 64)
    Head of Research
  • Dr. Paul Shabram M.B.A.
    Head of Technical Operations














BIOR Stock Analysis - Frequently Asked Questions

Should I buy or sell Biora Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biora Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOR shares.
View BIOR analyst ratings
or view top-rated stocks.

How have BIOR shares performed in 2023?

Biora Therapeutics' stock was trading at $82.3125 at the start of the year. Since then, BIOR shares have decreased by 98.4% and is now trading at $1.35.
View the best growth stocks for 2023 here
.

Are investors shorting Biora Therapeutics?

Biora Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 653,700 shares, an increase of 28.6% from the October 31st total of 508,200 shares. Based on an average daily volume of 166,500 shares, the days-to-cover ratio is currently 3.9 days. Currently, 2.9% of the company's stock are short sold.
View Biora Therapeutics' Short Interest
.

When is Biora Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our BIOR earnings forecast
.

How were Biora Therapeutics' earnings last quarter?

Biora Therapeutics, Inc. (NASDAQ:BIOR) announced its earnings results on Wednesday, November, 10th. The company reported ($0.46) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.01. The firm had revenue of $0.18 million for the quarter, compared to analyst estimates of $11.10 million. During the same quarter last year, the firm earned ($1.01) earnings per share.

When did Biora Therapeutics' stock split?

Biora Therapeutics shares reverse split on the morning of Tuesday, January 3rd 2023. The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are Biora Therapeutics' major shareholders?

Biora Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Sabby Management LLC (2.71%), Group One Trading L.P. (0.00%), Cutler Group LLC CA (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Athyrium Capital Management, L, Damon Silvestry, Harry Stylli, Jeffrey D Alter and Surbhi Sarna.
View institutional ownership trends
.

How do I buy shares of Biora Therapeutics?

Shares of BIOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BIOR) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -